Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

347 ARTÍCULOS , VIENDO DEL 76 AL 90

Cardiac safety of donepezil in elderly patients with Alzheimer disease

Isik AT, Yildiz GB, Bozoglu E, Yay A, Aydemir E.

Intern Med. 2012;51(6):575-8. doi: 10.2169/internalmedicine.51.6671. Epub 2012 Mar 15.

The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update

Bales KR.

Expert Opin Drug Discov. 2012 Apr;7(4):281-97. doi: 10.1517/17460441.2012.666234. Epub 2012 Feb 23.

Integrating cytosolic phospholipase A₂ with oxidative/nitrosative signaling pathways in neurons: a novel therapeutic strategy for AD

Sun GY, He Y, Chuang DY, Lee JC, Gu Z, Simonyi A, Sun AY.

Mol Neurobiol. 2012 Aug;46(1):85-95. doi: 10.1007/s12035-012-8261-1. Epub 2012 Apr 3.

Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors

Versijpt J.

Acta Neurol Belg. 2012 Jun;112(2):141-5. doi: 10.1007/s13760-012-0062-9. Epub 2012 Apr 4.

Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses

Pouryamout L, Dams J, Wasem J, Dodel R, Neumann A.

Drugs. 2012 Apr 16;72(6):789-802. doi: 10.2165/11631830-000000000-00000.

Editorial: Anti Alzheimer agents

Hugel H.

Mini Rev Med Chem. 2012 May;12(5):363. doi: 10.2174/138955712800493889.

Recruitment, retention and other methodological issues related to clinical trials for Alzheimer's disease

Vellas B.

J Nutr Health Aging. 2012 Apr;16(4):330. doi: 10.1007/s12603-012-0043-y.

Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial)

Carrié I, van Kan GA, Gillette-Guyonnet S, Andrieu S, Dartigues JF, Touchon J, Dantoine T, Rouaud O, Bonnefoy M, Robert P, Cuffi MN, Bories L, Bordes S, Gasnier Y, Desclaux F, Sudres K, Pesce A, Vellas B.

J Nutr Health Aging. 2012 Apr;16(4):355-9. doi: 10.1007/s12603-012-0046-8.

Does lithium prevent Alzheimer's disease?

Forlenza OV, de Paula VJ, Machado-Vieira R, Diniz BS, Gattaz WF.

Drugs Aging. 2012 May 1;29(5):335-42. doi: 10.2165/11599180-000000000-00000.

Small-molecule BACE1 inhibitors: a patent literature review (2006 - 2011)

Probst G, Xu YZ.

Expert Opin Ther Pat. 2012 May;22(5):511-40. doi: 10.1517/13543776.2012.681302. Epub 2012 Apr 19.

Mitochondria, diabetes, and Alzheimer's disease

Milone M.

Diabetes. 2012 May;61(5):991-2. doi: 10.2337/db12-0209.

Possible usefulness of growth hormone/insulin-like growth factor-I axis in Alzheimer's disease treatment

Sáez JM.

Endocr Metab Immune Disord Drug Targets. 2012 Sep;12(3):274-86. doi: 10.2174/187153012802002857.

Opioid system and Alzheimer's disease

Cai Z, Ratka A.

Neuromolecular Med. 2012 Jun;14(2):91-111. doi: 10.1007/s12017-012-8180-3. Epub 2012 Apr 22.

Cotinine: a potential new therapeutic agent against Alzheimer's disease

Echeverria V, Zeitlin R.

CNS Neurosci Ther. 2012 Jul;18(7):517-23. doi: 10.1111/j.1755-5949.2012.00317.x. Epub 2012 Apr 25.

[Intended pharmacotherapeutical approaches of Alzheimer's disease therapy]

Korábecný J, Hrubá E, Soukup O, Zemek F, Musílek K, Nepovímová E, Spilovská K, Opletalová V, Kuca K.

Ceska Slov Farm. 2012 Feb;61(1-2):4-10.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias